Skip to content

Randomized Comparison of DCB for the Treatment of Superficial Femoral and Popliteal Peripheral Artery Disease

Randomized Comparison of Drug-Coated Balloons for the Treatment of Superficial Femoral and Popliteal Peripheral Artery Disease: Prospective, Multicenter, Randomized, Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02648334
Acronym
DCB-SFA
Enrollment
443
Registered
2016-01-07
Start date
2016-11-10
Completion date
2024-08-07
Last updated
2024-08-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Angioplasty, Balloon, Catheterization, Peripheral, Femoral Artery, Popliteal Artery

Keywords

Drug-Coated Balloon, Superficial Femoral artery, popliteal peripheral Artery

Brief summary

This study evaluates the safety and effectiveness Percutaneous Transluminal Angioplasty(PTA) using Drug-Coated Balloons for the treatment of Superficial Femoral and popliteal peripheral Artery disease.

Interventions

DEVICEIN.PACT drug coated balloon

Sponsors

Seung-Whan Lee, M.D., Ph.D.
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age 19 and above * Subject with claudication or critical limb ischemia(Rutherford classification level 2\ 5) * Subject with total occlusion or stenosis ≥70%(de novo, restenosis) * Vessel diameter 4\ 6mm * Success to guide wire pass * Patients who don't have known hypersensitivity or allergy for dual-platelets * Willing and able to provide informed written consent

Exclusion criteria

* Acute stage * Acute thrombosis in target limb or target vessel * Failure to guide wire pass * Distal outflow * Lesion with poor inflow * Life expectancy ≤ 2 years * Allergic to paclitaxel * Pregnant or breast feeding woman or disagree with contraception or having children

Design outcomes

Primary

MeasureTime frameDescription
the event rate of composite event1 yearall cause death, revascularization due to amputation or clinical evidence

Secondary

MeasureTime frameDescription
target lesion revascularization2 years
The change of Rutherford classification2 years
The change of ABI(ankle-brachial index) score2 years
MACE2 yearsmajor adverse cardiac event(death, myocardial infarction, stroke)
amputation of target limb2 years
cardiac death2 years
myocardial infarction2 years
stroke2 years
thrombosis2 years
all cause death2 years

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026